IBC-Ab002 

IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease^[1][2].

Human

IBC-Ab002 reduces premature diabetes onset, shows no excessive weight loss or early mortality in NOD mice (200 days), enhances toxic substance clearance, improves neuronal function and reduces inflammation in AD mouse models, depends on Cmax for efficacy^[1][2].
IBC-Ab002 presents favorable pharmacokinetic and safety profiles in healthy cynomolgus monkeys in vivo^[1][2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

29126  [NCBI]

Q9NZQ7

B7-H1/PD-L1/CD274

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Baruch K, et al. IBC-Ab002, an anti-PD-L1 monoclonal antibody tailored for treating Alzheimer’s disease. Alzheimers Dement. 2020 Dec;16(S9):e042978.

  [2]. Kertser A, et al. IBC-Ab002 Fc modifications for fast clearance are associated with advantageous safety profile. Alzheimers Dement. 2023 Dec;19(S21):e075622.